All Oncology News

Jason J. Luke, MD, FACP, discusses data for the PRAME-targeted TCR T-cell therapy IMA203 in advanced or metastatic melanoma.

Liquid biopsy approaches aid in precision therapy selection for patients with breast cancer in a noninvasive manner.

Hope S. Rugo, MD, FASCO, discusses key considerations and unanswered questions arising from the DESTINY-Breast09 trial in HER2-positive breast cancer.

First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.

Sarah Sammons, MD, discusses data from the phase 1 ReDiscover trial of RLY-2608 plus fulvestrant in HR-positive, HER2-negative breast cancer.

Sara M. Tolaney, MD, MPH, discusses data showing that T-DXd plus pertuzumab improved PFS vs SOC THP in first-line HER2-positive breast cancer.

Clinical trial tests new treatment approach, offers hope for personalized therapies.

The Center for Drug Evaluation of the Chinese NMPA has accepted the marketing authorization application for pimicotinib in patients with TGCT.

The FDA granted priority review to the sNDA seeking the approval of the first-line maintenance combination of lurbinectedin and atezolizumab for ES-SCLC.

Rana R. McKay, MD, discusses data from the COMRADE trial, which showed that olaparib plus radium-223 improved rPFS in men with mCRPC with bone metastases.

A deep dive into the phase 3b ABLE-32 trial reveals the need for more treatments for patients with intermediate-risk NMIBC.

Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.

UGN-102 showed strong responses in patients with recurrent, intermediate-risk, low-grade non–muscle-invasive bladder cancer, per the phase 3 ENVISION trial.

The FDA granted fast track designation to PHST001 for patients with ovarian cancer.

David J. Benjamin, MD, discusses how he uses real-world data to supplement clinical trial results in urothelial carcinoma.

OS Therapies submits a RMAT designation request for OST-HER2 for the treatment of patients with pediatric lung-metastatic osteosarcoma.

The FDA has lifted the partial clinical hold on a phase 3 study assessing IFx-2.0 in advanced Merkel cell carcinoma.

Daneng Li, MD, discusses the IL-27–targeted agent casdozokitug in hepatocellular carcinoma.

Erica L. Mayer, MD, MPH, discusses the implications of data from the SERENA-6 trial for ESR1 testing in hormone receptor–positive breast cancer.

Suresh S. Ramalingam, MD, FACP, FASCO, highlights his journey in the lung cancer field, leading up to his recognition on the TIME100 Health 2025 list.

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

Tess O’Meara, MD, discusses the implications of data from the DESTINY-Breast09 trial of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Elizabeth Mittendorf, MD, PhD, MHCM, discusses advancing ASCO’s mission through research advocacy, global collaboration, and a commitment to equity.

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.